Novo Nordic shares popping 6% after better thanex than expected trial results from its so-called Wgoi pill. Angelica Peebles is here with more. So much coming out this week in the weight loss space.It has been quite a busy week, I can uh assure you that. But this data definitely impressing. So this was actually not presented at that conference but still coming amid this big week where we have all of these different presentations coming out of this diabetes conference in Vienna.But the headline here is that ...

and the obesity pill race. Mizuo healthcare strategist Jared Holtz joins us here on the set. You know, beyond just the patients being nauseous, investors are too today, down 42%.Is this it. I mean, are they done. Is Viking Therapeutics out of this race for the obesity pill.>> I don't think they're done. I mean, it's a it's a big setback for sure. It's going to come down to what the next trial looks like, what the dosing is, but this sort of discontinuation rate when you have monster companies that are ahead ...

Eli Lilly's Stock Performance & Market Reaction - Eli Lilly's stock tumbled to its lowest level since January 2024 despite beating estimates and raising guidance for the latest quarter [1] - The stock reaction is attributed to trial data for its oral obesity pill, Clipperon, missing Wall Street's expectations [5] - Goldman Sachs views the stock reaction as overdone, considering the drug commercially viable [6] Oral Obesity Pill Trial Results & Expectations - The goal was to create a convenient oral pill for the mass market with weight loss competitive with other single-acting GLP1s [2] - Wall Street expected weight loss closer to the mid-teens, around 14-15%, but the trial results were just shy of that [6] - The Attain One trial for the oral obesity pill missed the "bar" [5] - The company frames the tolerability as in line with or trending towards bull-case expectations, with no significant new events in terms of nausea or vomiting [10] Commercial Viability & Market Opportunity - The oral obesity pill is still considered commercially viable and will have a place in the large obesity market [7] - The oral obesity market may see a repricing, potentially shifting opportunity from Eli Lilly's gipperon to Novo Nordisk's oral semaglutide [12] - The overall obesity opportunity remains significant, with about 100 million obese people in the US and 900 million overseas, with low penetration rates for GLP-1 drugs [13] - Current GLP-1 drugs are only 3% penetrated in the US, with expectations of reaching 15% by 2030 [13]